Add Company
Join Now

Elephas Revenue and Competitors

License our Company Data API

Madison, WI USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Elephas's estimated annual revenue is currently $26.5M per year.(i)
  • Elephas's estimated revenue per employee is $155,000

Employee Data

  • Elephas has 171 Employees.(i)
  • Elephas grew their employee count by 20% last year.

Elephas's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
Co-Founder & Senior Scientific AdvisorReveal Email/Phone
3
Head Talent AcquisitionReveal Email/Phone
4
Head Commercial Operations and Customer SuccessReveal Email/Phone
5
VP Precision OncologyReveal Email/Phone
6
VP Quality and RegulatoryReveal Email/Phone
7
VP TechnologyReveal Email/Phone
8
VP BioPharma ServicesReveal Email/Phone
9
ControllerReveal Email/Phone
10
VP Research And DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M1820%N/AN/A
#2
$1.9M1233%N/AN/A
#3
$1.1M70%N/AN/A
#4
$0.9M60%N/AN/A
#5
$5.2M670%$45.5MN/A
#6
$1.4M90%N/AN/A
#7
$1.6M100%N/AN/A
#8
$1.1M717%N/AN/A
#9
$13.5M87-17%N/AN/A
#10
$0.6M4-20%N/AN/A
Add Company

What Is Elephas?

Elephas is developing an imaging platform technology to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development

keywords:N/A

N/A

Total Funding

171

Number of Employees

$26.5M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M1714%N/A
#2
$39.5M171N/AN/A
#3
$26.7M171-2%N/A
#4
$62.4M172-1%N/A
#5
$31.4M1736%N/A